<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antiphospholipid syndrome and the kidney</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antiphospholipid syndrome and the kidney</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antiphospholipid syndrome and the kidney</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald B Appel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter H Schur, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by persistent autoantibodies directed against either phospholipids or plasma proteins bound to anionic phospholipids [<a href="#rid1">1,2</a>]. The pathogenesis of the syndrome is complex, involving a multiplicity of factors [<a href="#rid2">2</a>]. Patients with the APS may display a constellation of clinical features including venous, arterial, and microvascular thromboses, which can be associated with valvular heart disease, thrombocytopenia, livedo reticularis, neurologic findings, and recurrent fetal losses [<a href="#rid1">1</a>].</p><p>Antiphospholipid-related kidney disease, and so-called antiphospholipid nephropathy, may be found with any of these other clinical features. This disorder is referred to as the primary APS when it occurs alone without another associated autoimmune disease. Among patients with systemic lupus erythematosus (SLE), 20 to 30 percent will have clinically relevant elevated levels of antiphospholipid antibody titers [<a href="#rid3">3</a>]. Elevated antibody titers can also be found in other rheumatic diseases, with certain infections, in patients taking specific medications, and among patients with pregnancy complications, venous thromboses, or stroke [<a href="#rid4">4</a>].</p><p>Types of antiphospholipid antibodies (aPL) that have been characterized include:</p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies causing a false-positive Venereal Disease Research Laboratory (VDRL) test</p><p class="bulletIndent1"><span class="glyph">●</span>Lupus anticoagulants</p><p class="bulletIndent1"><span class="glyph">●</span>Anticardiolipin antibodies (aCL)</p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to beta2-glycoprotein I</p><p></p><p>There appears to be a relationship between the isotype and titer of aPL and the risk of thrombotic events. Higher titers of immunoglobulin G (IgG) aPL, for example, are associated with a greater incidence of thrombotic events [<a href="#rid5">5</a>].</p><p>The kidney is one of the organs that may be involved in APS. Kidney complications may directly result from thrombotic events associated with these antibodies, including microvascular glomerular disease, large vessel arterial and venous renal thromboses, chronic vasoocclusive disease, and coagulation problems relating to dialysis or kidney transplantation [<a href="#rid5">5-12</a>].</p><p>The pathology, manifestations, and treatment of kidney involvement in patients with APS are presented here. General discussions of the clinical manifestations, diagnosis, and treatment of this disorder are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4678.html" rel="external">"Diagnosis of antiphospholipid syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">KIDNEY MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME</span><span class="headingEndMark"> — </span>The prevalence of kidney involvement in patients with primary antiphospholipid syndrome (APS) has been reported in up to 25 percent, although the frequency is far lower in most series [<a href="#rid5">5,7-9,12,13</a>]. In one cohort of 160 patients with primary APS from Northern Italy, signs of kidney involvement were present in 9 percent of patients [<a href="#rid14">14</a>]. Antiphospholipid antibodies (aPL) frequently occur in patients with lupus, in whom kidney disease is more frequently caused by immune deposits. (See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Kidney disease in primary APS</span><span class="headingEndMark"> — </span>Kidney involvement in primary APS is generally characterized pathologically by noninflammatory occlusion of a broad spectrum of renal blood vessels, ranging from glomerular capillaries to the main renal artery and vein  (<a class="graphic graphic_picture graphicRef63511 graphicRef54840 graphicRef69687 graphicRef75317" href="/d/graphic/63511.html" rel="external">picture 1A-D</a>) [<a href="#rid8">8,12,15-18</a>].</p><p class="headingAnchor" id="H2553112785"><span class="h3">aPL-associated nephropathy</span><span class="headingEndMark"> — </span>When small renal vessels, such as glomerular capillaries, are involved, the pathological findings resemble those found in other diseases associated with a thrombotic microangiopathy (TMA), including the hemolytic-uremic syndrome, and thrombotic thrombocytopenic purpura. When seen in patients with aPL, they have been called "aPL-associated nephropathy" [<a href="#rid5">5,7,8,13,19</a>] (see  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Involved arteries and arterioles often have a thrombotic lesion, resulting in reactive intimal mucoid thickening, subendothelial fibrosis, and medial hyperplasia [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Affected glomerular capillaries reveal thrombi with associated mesangiolysis, mesangial interposition along the glomerular capillary wall, and electron lucent areas in the subendothelial space.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal atrophy of the cortex in association with interstitial fibrosis may be observed, presumably resulting from tissue ischemia.</p><p></p><p>If kidney biopsy is performed later in the course of the disease, focal segmental glomerulosclerosis may be a prominent finding as a sequel of the glomerular TMA [<a href="#rid20">20</a>].</p><p>The clinical features associated with the thrombi in the glomeruli and small arteries are variable [<a href="#rid21">21</a>]. Some patients have only asymptomatic, mild proteinuria (&lt;2 g/day) with normal kidney function, while others develop acute or subacute kidney injury with proteinuria (which can reach the nephrotic range), an active urine sediment (that can include red cell casts), and often marked hypertension [<a href="#rid8">8,15,22</a>].</p><p class="headingAnchor" id="H486294146"><span class="h3">Large vessel disease</span><span class="headingEndMark"> — </span>Large renal arterial thrombosis with renal infarction can present with unilateral or bilateral flank pain, hematuria, and decreased kidney function [<a href="#rid5">5,7,8,13</a>]. Renal angiography, or computed tomography or magnetic resonance angiography (MRA) should be performed to confirm the diagnosis. APS can be also associated with arterial disease and hypertension without evidence of thrombosis of the renal arteries [<a href="#rid23">23,24</a>]. In one study of 260 patients, for example, 26 percent of those with uncontrolled hypertension and APS were found to have renal artery stenosis by MRA [<a href="#rid23">23</a>].</p><p>Renal vein thrombosis, when it occurs, may be silent or, if acute and complete, may present with sudden flank pain and a decrease in kidney function [<a href="#rid11">11,25</a>].</p><p class="headingAnchor" id="H19782557"><span class="h3">Other glomerular lesions associated with primary APS</span><span class="headingEndMark"> — </span>Other glomerular lesions that have been described in patients with primary APS including membranous nephropathy, minimal change disease, and pauci-immune glomerulonephritis [<a href="#rid14">14,26</a>]. In a retrospective study of 160 patients who were diagnosed with primary APS, kidney involvement (defined as serum creatinine &gt;1.4 mg/dL [124 micromol/L] and/or proteinuria &gt;0.3 g/day with or without hematuria) was identified in 14 [<a href="#rid14">14</a>]. Ten of the 14 patients had a kidney biopsy that showed membranous nephropathy (n = 4), diffuse proliferative glomerulonephritis (n = 2), TMA (n = 2), and vascular lesions consistent with chronic antiphospholipid nephropathy (n = 2). Both patients who had diffuse proliferative glomerulonephritis developed full-blown lupus 13 and 18 years after the diagnosis of primary APS. At a mean follow-up of 8.5 years (range 6.9 to 14 years), none of the patients with membranous nephropathy had developed clinical evidence of lupus, although it is possible that lupus-related signs or symptoms were suppressed by immunosuppressive therapy.</p><p class="headingAnchor" id="H4"><span class="h2">Kidney disease in APS associated with systemic lupus erythematosus</span><span class="headingEndMark"> — </span>Patients with lupus and aPL commonly have a history of systemic thromboses, fetal loss, neurologic disorders, and thrombocytopenia [<a href="#rid5">5,27,28</a>]. In patients with lupus, the principal laboratory features that correlate with the presence of high titers of immunoglobulin G (IgG) aPL are thrombocytopenia, the presence of a false-positive Venereal Disease Research Laboratory (VDRL) test for syphilis (fluorescent treponemal antibody [FTA] negative), and a prolonged activated partial thromboplastin time (aPTT) [<a href="#rid5">5,12,29</a>]. Kidney disease in this setting may result from microthrombi and/or deposits of immune complexes.</p><p>Isolated microangiopathic thrombosis is a relatively unusual finding in patients with APS and lupus. Only approximately 10 percent of such patients in whom kidney biopsies are performed show glomerular microthromboses as the major<strong> </strong>histopathologic finding. Nevertheless, aPL can cause significant kidney damage in patients with lupus [<a href="#rid19">19,30</a>]. These histologic and clinical features are similar to those with the APS alone or those with lupus-like features in whom the American Rheumatism Association (ARA) criteria for a diagnosis of systemic lupus erythematosus (SLE) are not fulfilled [<a href="#rid19">19,30</a>].</p><p>To better address the relationships among thrombi, aPL, kidney dysfunction, and traditional lupus nephritis, a retrospective study evaluated the findings on kidney biopsy in 114 patients with SLE and kidney dysfunction [<a href="#rid31">31</a>]. The following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Vaso-occlusive lesions were found in approximately one-third of biopsies in addition to, or independent of, traditional immune complex lupus nephritis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombi independently contributed to elevations in the serum creatinine concentration and the development of hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of renal thrombi correlated with the presence of a lupus anticoagulant, but not with anticardiolipin antibodies (aCL).</p><p></p><p>APS in patients with SLE can occur in addition to and independent of lupus nephritis [<a href="#rid31">31,32</a>]. In a review of 111 patients with lupus nephritis who were followed for a mean of almost 15 years and were tested regularly for aCL and lupus anticoagulant, the overall prevalence of aPL was 26 percent. aPL occurred more frequently in patients with membranous lupus (50 versus 22 percent with other lesions).</p><p>It is important to document the presence of glomerular microthromboses in patients with the APS and SLE since the therapy for TMA differs from the immunosuppression required for immune complex-mediated lupus nephritis. Such thrombi often recanalize in the absence of an inflammatory infiltrate and in the absence of immune deposits on immunofluorescence or electron microscopy.</p><p>The relationship between aPL and the overall risk of progressive chronic kidney disease (CKD) is not entirely clear [<a href="#rid32">32-34</a>]. A prospective, long-term study (median follow-up of 167 months) evaluated 111 patients with lupus nephritis, of whom 29 had aPL [<a href="#rid32">32</a>]. There was a significant correlation between antibody presence and the eventual development of CKD (relative risk [RR] 2.2). Although not all studies have confirmed such an association between the presence of aPL and a progressive kidney course [<a href="#rid34">34</a>], most studies confirm that the presence of thrombotic nephropathy in patients with lupus nephritis is an independent risk factor for a poor kidney outcome [<a href="#rid35">35,36</a>].</p><p>The presence of aPL may also be associated with a higher mortality in patients with lupus nephritis [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H5"><span class="h1">ANTIPHOSPHOLIPID SYNDROME IN END-STAGE KIDNEY DISEASE</span><span class="headingEndMark"> — </span>Antiphospholipid antibodies (aPL) can occur in patients with end-stage kidney disease treated with maintenance hemodialysis or kidney transplantation. (See  <a class="medical medical_review" href="/d/html/1971.html" rel="external">"Hemodialysis arteriovenous graft dysfunction and failure"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Hemodialysis</span><span class="headingEndMark"> — </span>Several studies have found that patients on maintenance hemodialysis have a high prevalence of aPL, a finding associated with an increased incidence of thrombotic events [<a href="#rid38">38-41</a>]. In one study, for example, aPL were present in 31 percent of 97 hemodialysis patients (the lupus anticoagulant and anticardiolipin antibodies [aCL] in 17 and 16 percent, respectively) [<a href="#rid38">38</a>]. The frequency of vascular access thrombosis was much higher in the patients with aPL, as measured by the lupus anticoagulant (62 versus 26 percent in those without these antibodies). Similar findings were noted in another report in which a significant increase in the odds of having two or more episodes of arteriovenous (AV) graft thrombosis was found among the patients with raised aPL titers [<a href="#rid39">39</a>].</p><p>The incidence of aPL may vary with the type of hemodialysis access used. This was suggested in a cross-sectional study that evaluated hemodialysis patients at a single dialysis facility: 22 percent of 74 patients with AV grafts had a raised titer of immunoglobulin G (IgG) aPL versus only 1 of 17 patients (6 percent) with AV fistulas [<a href="#rid39">39</a>]. Whether AV grafts induce aPL or patients with aPL require AV grafts could not be determined.</p><p>The experience at one major medical center lends further support to these findings. In a review of 230 patients undergoing chronic hemodialysis, the following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Titers of IgG aPL were elevated in 26 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Titers of immunoglobulin M (IgM) aPL were elevated in 4 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Titers of both antibodies were elevated in 3 percent</p><p></p><p>The mean time to AV graft failure was significantly decreased in the group with elevated IgG antibodies, even though there was no difference in AV fistula clotting between those with and without high IgG antibody titers.</p><p>There does not appear to be an association between the development of aPL and age, sex, or dialysis duration [<a href="#rid38">38</a>]. However, the incidence of such antibodies appears to correlate positively with the type of dialysis modality as well as the use of dialysis since a much lower incidence of aPL has been found both in patients with kidney function impairment in whom dialytic support is not yet required and in those treated with peritoneal dialysis [<a href="#rid40">40,42,43</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Kidney transplantation</span><span class="headingEndMark"> — </span>There is increasing evidence that patients with a positive aPL or the antiphospholipid syndrome (APS) have a worse outcome after kidney transplantation [<a href="#rid5">5,44,45</a>]. In one series of over 1300 kidney recipients, lupus anticoagulant-positive patients had a high rate of vascular damage in their allograft and poor one-year outcomes [<a href="#rid44">44</a>]. A substantial number of kidney transplant recipients have circulating aPL, which can damage the allograft [<a href="#rid46">46-48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 178 transplant recipients, 28 percent had aPL [<a href="#rid47">47</a>]. Compared with patients without such antibodies, these individuals had a significantly higher incidence of arterial (18 versus 6 percent, p&lt;0.001) and venous (8 versus 2 percent, p&lt;0.001) thrombosis; testing of pretransplant sera revealed that the aPL were present prior to the operation in 85 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second retrospective series, which evaluated transplant recipients with systemic lupus erythematosus (SLE), also found a high incidence of significant thrombotic events among those with aPL (60 versus 8 percent in patients without these antibodies) [<a href="#rid49">49</a>].</p><p></p><p>Although suggestive, these retrospective observations cannot prove causality. Another retrospective study, for example, reported no increased incidence in allograft loss or reduction in glomerular filtration rate among the 61 of 337 patients with positive aCL. In this study, there was increased use of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in those with positive antibodies (20 versus 7 percent) [<a href="#rid50">50</a>]. However, early allograft loss was observed in two of five patients with very high aCL titers who were not being anticoagulated.</p><p>In addition to systemic thrombotic events, a renal thrombotic microangiopathy (TMA) may be observed in hepatitis C virus (HCV)-infected kidney transplant recipients with aCL. This association was suggested in a report of 18 anti-HCV-positive patients, five of whom developed renal TMA between 5 and 120 days after transplantation [<a href="#rid51">51</a>]. aPL were found in all five of these patients but in only 1 of the 13 without a microangiopathy. The hypothesis that aCL, HCV infection, and renal thrombosis were correlated was supported by the observation that normal aCL titers were found in the seven HCV-negative transplant recipients who presented with renal TMA/hemolytic-uremic syndrome during the same time period and served as a control group.</p><p class="headingAnchor" id="H8"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of patients with antiphospholipid syndrome APS who have kidney disease is generally similar to that of patients without kidney disease [<a href="#rid5">5,7,8,13,52</a>]. Patients with evidence of venous or arterial thromboembolic disease, thrombotic microangiopathy (TMA) in the glomeruli and small arteries, or thrombi in the larger vessels must be treated to avoid life-threatening vascular damage. In general, patients with APS-associated kidney disease should be anticoagulated with vitamin K antagonists [<a href="#rid53">53</a>]. Although not applicable to all patients with APS, data suggest that anti-factor Xa therapy with either <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> or <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> is inferior to vitamin K antagonist therapy [<a href="#rid54">54-56</a>]. (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p>Treatment of catastrophic APS (CAPS) is presented separately. (See  <a class="medical medical_review" href="/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)", section on 'Management'</a>.)</p><p>Issues related to the general therapy of thromboembolic events in patients with the APS are discussed in detail elsewhere. Summarized briefly, moderate-intensity <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (target international normalized ratio [INR] of 2 to 3) appears to be as effective as more intensive anticoagulation [<a href="#rid57">57,58</a>]. (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Secondary thrombosis prevention'</a>.)</p><p>The use of antithrombotic therapy for primary prevention in APS is controversial. Because many patients with antiphospholipid antibodies (aPL) do not experience thrombotic events or have evidence of renal thrombosis, indiscriminate anticoagulation of such patients places a large population at risk for bleeding to achieve a dubious benefit. However, some experts recommend low dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> for asymptomatic carriers of aPL [<a href="#rid53">53</a>]. It is reasonable to administer prophylactic anticoagulation to some patients with aPL who have other conditions associated with high thrombotic risk. For example, patients with APS who have membranous nephropathy may warrant prophylactic anticoagulation, even if nephrotic syndrome and low serum albumin concentrations are absent. (See  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome", section on 'Prevention of thromboembolism'</a>.)</p><p>Immunosuppressive therapy generally has little effect on the titers of aPL. Most immunosuppressive agents have been used in isolated cases or small numbers with varied success [<a href="#rid59">59</a>]. However, <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>, a humanized monoclonal antibody against the fifth component of complement, has been successful in rare anecdotal cases to treat recurrent thromboses after kidney transplantation [<a href="#rid60">60,61</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Hemodialysis</span><span class="headingEndMark"> — </span>Patients with APS treated with hemodialysis have an increased incidence of recurrent thrombosis in arteriovenous (AV) grafts [<a href="#rid38">38-41</a>]. In such patients, treatment with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> may increase AV graft survival [<a href="#rid6">6</a>]. However, given the risks of bleeding in anticoagulated patients, many would only anticoagulate patients who have repeat AV graft clotting.</p><p class="headingAnchor" id="H10"><span class="h2">Kidney transplantation</span><span class="headingEndMark"> — </span>Patients with a positive aPL or the APS have a worse outcome after kidney transplantation than those without these findings [<a href="#rid5">5</a>]. Patients with systemic lupus erythematosus (SLE), a positive aPL, a history of thromboembolic events and lupus nephritis, as well as those with the APS, may benefit from continued <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> therapy after kidney transplantation [<a href="#rid62">62-64</a>]. If untreated, these patients appear to be at risk for both intrarenal and systemic clotting events [<a href="#rid46">46,50,62</a>]. Based on the incomplete data, many transplant nephrologists anticoagulate all patients with aPL and a history of coagulation events during the peritransplant period. It is unknown how long such treatment should be continued or whether it should be continued indefinitely. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>One study reported the outcomes of 11 kidney transplant recipients with the APS, of whom four were treated with anticoagulant therapy after transplantation [<a href="#rid62">62</a>]. All seven patients not administered anticoagulants lost their allograft to renal thrombosis within one week of surgery; by comparison, three of four treated patients had functioning allografts for over two years, but the remaining patient also thrombosed his graft within one week of the procedure. No allografts were lost to renal thrombosis among 37 other patients with high titers of anticardiolipin antibodies (aCL) but no previous history of thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A protective effective of anticoagulation was also suggested in another report in which five patients at high risk for thrombosis were treated preemptively with postoperative heparin and subsequently with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid65">65</a>]. Allograft thrombosis occurred in one patient who received <a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> rather than warfarin. The target INR for warfarin therapy was 2.0 to 2.5.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibitors of the mammalian target of rapamycin (mTOR) may decrease the recurrence of APS-associated vascular lesions among kidney transplant recipients [<a href="#rid66">66</a>]. The activation of mTOR signalling pathways was demonstrated in cultured vascular endothelial cells treated with immunoglobulin G (IgG) antibodies from patients with APS. Allograft biopsies from 10 transplant recipients with aPL who were receiving the mTOR inhibitor, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, showed decreased hyperplasia of endothelial cells compared with biopsies from 27 patients with aPL who did not receive sirolimus. Additionally, allograft function appeared to be better preserved among APS patients who received sirolimus. This observational study offers insights into the pathogenesis of APS but requires independent confirmation before recommendations regarding treatment can be made [<a href="#rid67">67</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Acute kidney injury</span><span class="headingEndMark"> — </span>Selected patients with acute kidney injury (AKI) may respond either to plasmapheresis, which presumably acts by removing the pathogenic antibody [<a href="#rid8">8,9,68</a>], or to corticosteroids and chronic anticoagulation [<a href="#rid69">69</a>]. In an uncontrolled report of 12 patients, for example, complete kidney function recovery occurred only in the two patients treated with plasma exchange [<a href="#rid8">8</a>].</p><p>The optimal apheresis regimen for AKI is uncertain. However, a prescription of three to five one-plasma volume exchanges over a seven-day period should produce substantial lowering of aPL levels. (See  <a class="medical medical_review" href="/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"</a>.)</p><p class="headingAnchor" id="H3799623648"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110752.html" rel="external">"Society guideline links: Acute kidney injury in adults"</a>.)</p><p class="headingAnchor" id="H13319968"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/575.html" rel="external">"Patient education: Antiphospholipid syndrome (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/581.html" rel="external">"Patient education: Systemic lupus erythematosus (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4414.html" rel="external">"Patient education: Hemodialysis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/4418.html" rel="external">"Patient education: Dialysis or kidney transplantation — which is right for me? (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – The antiphospholipid syndrome (APS) is characterized by antibodies directed against phospholipids or plasma proteins bound to phospholipids. APS may occur alone (primary APS) or in association with systemic lupus erythematosus (SLE), other rheumatic diseases, and certain infections and medications. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney disease in primary APS</strong> – Primary APS causes noninflammatory occlusion of renal blood vessels that, depending on the type of the involved blood vessels, results in renal infarction, ischemic changes, or in thrombotic microangiopathy (TMA) involving the glomeruli. (See <a class="local">'Kidney disease in primary APS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiphospholipid-associated nephropathy</strong> – Among patients with glomerular involvement, histology often resembles the hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. In this setting, the lesion has been called antiphospholipid-associated nephropathy. (See <a class="local">'aPL-associated nephropathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Large vessel disease</strong> – Patients who have large vessel involvement present with unilateral or bilateral flank pain, hematuria, and decreased kidney function. (See <a class="local">'Large vessel disease'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other glomerular lesions</strong> – Other glomerular lesions that may be observed include membranous nephropathy, minimal change disease, and pauci-immune glomerulonephritis. (See <a class="local">'Other glomerular lesions associated with primary APS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>APS associated with SLE</strong> – Patients with APS associated with SLE present with systemic thromboses, fetal loss, neurologic disorders, thrombocytopenia, a false-positive Venereal Disease Research Laboratory (VDRL) test for syphilis, and a prolonged activated partial thromboplastin time (aPTT). Among such patients, kidney disease may result from microthrombi and/or deposits of immune complexes. (See <a class="local">'Kidney disease in APS associated with systemic lupus erythematosus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>APS in end-stage kidney disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients on maintenance hemodialysis have a high prevalence of antiphospholipid antibodies (aPL) that are associated with an increased incidence of thrombotic events, often involving the vascular access. The incidence of such antibodies appears to correlate with the use of dialysis and with the type of dialysis but not with age, sex, or dialysis duration. (See <a class="local">'Hemodialysis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A substantial number of kidney transplant recipients have circulating aPL, which can damage the allograft. A renal TMA has also been observed in hepatitis C virus (HCV)-infected kidney transplant recipients with aPL. (See <a class="local">'Kidney transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The treatment of patients with APS who have kidney disease is generally similar to that of patients without kidney disease. Patients with TMA in the glomeruli and small arteries or thrombi in the larger vessels <strong>must</strong> be treated with anticoagulation to avoid life-threatening vascular damage. (See  <a class="medical medical_review" href="/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Catastrophic APS (CAPS)</strong> – Treatment of CAPS is presented separately. (See  <a class="medical medical_review" href="/d/html/106168.html" rel="external">"Catastrophic antiphospholipid syndrome (CAPS)", section on 'Management'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 2018; 378:2010.</a></li><li><a class="nounderline abstract_t">Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ 2023; 380:e069717.</a></li><li><a class="nounderline abstract_t">Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016; 3:75.</a></li><li><a class="nounderline abstract_t">Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken) 2013; 65:1869.</a></li><li><a class="nounderline abstract_t">Tektonidou MG. Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front Immunol 2018; 9:1181.</a></li><li><a class="nounderline abstract_t">Joseph RE, Radhakrishnan J, Appel GB. Antiphospholipid antibody syndrome and renal disease. Curr Opin Nephrol Hypertens 2001; 10:175.</a></li><li><a class="nounderline abstract_t">Bienaimé F, Legendre C, Terzi F, Canaud G. Antiphospholipid syndrome and kidney disease. Kidney Int 2017; 91:34.</a></li><li><a class="nounderline abstract_t">Turrent-Carriles A, Herrera-Félix JP, Amigo MC. Renal Involvement in Antiphospholipid Syndrome. Front Immunol 2018; 9:1008.</a></li><li><a class="nounderline abstract_t">Farrugia E, Torres VE, Gastineau D, et al. Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study. Am J Kidney Dis 1992; 20:463.</a></li><li><a class="nounderline abstract_t">Sonpal GM, Sharma A, Miller A. Primary antiphospholipid antibody syndrome, renal infarction and hypertension. J Rheumatol 1993; 20:1221.</a></li><li><a class="nounderline abstract_t">Asherson RA, Lanham JG, Hull RG, et al. Renal vein thrombosis in systemic lupus erythematosus: association with the "lupus anticoagulant". Clin Exp Rheumatol 1984; 2:75.</a></li><li><a class="nounderline abstract_t">Nicholls K, Kincaid-Smith P. Antiphospholipid syndrome and renal thrombotic microangiopathy. J Nephrol 1995; 8:123.</a></li><li><a class="nounderline abstract_t">Marcantoni C, Emmanuele C, Scolari F. Renal involvement in primary antiphospholipid syndrome. J Nephrol 2016; 29:507.</a></li><li><a class="nounderline abstract_t">Sinico RA, Cavazzana I, Nuzzo M, et al. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol 2010; 5:1211.</a></li><li><a class="nounderline abstract_t">D'Agati V, Kunis C, Williams G, Appel GB. Anti-cardiolipin antibody and renal disease: a report three cases. J Am Soc Nephrol 1990; 1:777.</a></li><li><a class="nounderline abstract_t">Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999; 10:507.</a></li><li><a class="nounderline abstract_t">Griffiths MH, Papadaki L, Neild GH. The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury. QJM 2000; 93:457.</a></li><li><a class="nounderline abstract_t">Aydin Z, Bruijn JA, Vleming LJ. ARF and cerebral infarcts in a young woman. Am J Kidney Dis 2004; 44:179.</a></li><li><a class="nounderline abstract_t">Tektonidou MG, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004; 50:2569.</a></li><li><a class="nounderline abstract_t">Saracino A, Ramunni A, Pannarale G, Coratelli P. Kidney disease associated with primary antiphospholipid syndrome: clinical signs and histopathological features in an case experience of five cases. Clin Nephrol 2005; 63:471.</a></li><li><a class="nounderline abstract_t">Nzerue CM, Hewan-Lowe K, Pierangeli S, Harris EN. "Black swan in the kidney": renal involvement in the antiphospholipid antibody syndrome. Kidney Int 2002; 62:733.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-1999. A 54-year-old woman with acute renal failure and thrombocytopenia. N Engl J Med 1999; 340:1900.</a></li><li><a class="nounderline abstract_t">Sangle SR, D'Cruz DP, Jan W, et al. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 2003; 62:999.</a></li><li><a class="nounderline abstract_t">Conti F, Ceccarelli F, Gigante A, et al. Ultrasonographic Evaluation of Resistive Index and Renal Artery Stenosis in Patients with Anti-Phospholipid Syndrome: Two Distinct Mechanisms? Ultrasound Med Biol 2015; 41:1814.</a></li><li><a class="nounderline abstract_t">Ko WS, Lim PS, Sung YP. Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome. Nephrol Dial Transplant 1995; 10:1929.</a></li><li><a class="nounderline abstract_t">Fakhouri F, Noël LH, Zuber J, et al. The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis 2003; 41:1205.</a></li><li><a class="nounderline abstract_t">Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682.</a></li><li><a class="nounderline abstract_t">Nast C, Appel G. A case of lupus nephritis. Clin J Am Soc Nephrol 2008; 3:297.</a></li><li><a class="nounderline abstract_t">Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 1993; 342:341.</a></li><li><a class="nounderline abstract_t">Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4:1499.</a></li><li><a class="nounderline abstract_t">Daugas E, Nochy D, Huong DL, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13:42.</a></li><li><a class="nounderline abstract_t">Moroni G, Ventura D, Riva P, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004; 43:28.</a></li><li><a class="nounderline abstract_t">Natejumnong C, Ruangkanchanasetr P, Aimpun P, Supaporn T. Significance of antiphospholipid antibodies in lupus nephritis. J Med Assoc Thai 2006; 89 Suppl 2:S121.</a></li><li><a class="nounderline abstract_t">Parodis I, Arnaud L, Gerhardsson J, et al. Antiphospholipid Antibodies in Lupus Nephritis. PLoS One 2016; 11:e0158076.</a></li><li><a class="nounderline abstract_t">Song D, Wu LH, Wang FM, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013; 15:R12.</a></li><li><a class="nounderline abstract_t">Wu LH, Yu F, Tan Y, et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013; 83:715.</a></li><li><a class="nounderline abstract_t">Yap DYH, Thong KM, Yung S, et al. Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes. Lupus 2019; 28:1460.</a></li><li><a class="nounderline abstract_t">Brunet P, Aillaud MF, San Marco M, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995; 48:794.</a></li><li><a class="nounderline abstract_t">Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995; 26:347.</a></li><li><a class="nounderline abstract_t">García-Martín F, De Arriba G, Carrascosa T, et al. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant 1991; 6:543.</a></li><li><a class="nounderline abstract_t">Prieto LN, Suki WN. Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies. Am J Kidney Dis 1994; 23:587.</a></li><li><a class="nounderline abstract_t">Radhakrishnan J, Williams GS, Appel GB, Cohen DJ. Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. Am J Kidney Dis 1994; 23:286.</a></li><li><a class="nounderline abstract_t">Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993.</a></li><li><a class="nounderline abstract_t">Canaud G, Bienaimé F, Noël LH, et al. Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies. Am J Transplant 2010; 10:2051.</a></li><li><a class="nounderline abstract_t">Gauthier M, Canoui-Poitrine F, Guéry E, et al. Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey. Nephrol Dial Transplant 2018; 33:709.</a></li><li><a class="nounderline abstract_t">Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68:366.</a></li><li><a class="nounderline abstract_t">Ducloux D, Pellet E, Fournier V, et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67:90.</a></li><li><a class="nounderline abstract_t">Kazory A, Ducloux D. Acquired hypercoagulable state in renal transplant recipients. Thromb Haemost 2004; 91:646.</a></li><li><a class="nounderline abstract_t">Stone JH, Amend WJ, Criswell LA. Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999; 34:1040.</a></li><li><a class="nounderline abstract_t">Forman JP, Lin J, Pascual M, et al. Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant 2004; 4:1786.</a></li><li><a class="nounderline abstract_t">Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10:146.</a></li><li><a class="nounderline abstract_t">Siniscalchi C, Rossetti P, Carolla G, et al. A review on management of antiphospholipid syndrome in clinical practice. Ital J Med 2023; 17.</a></li><li><a class="nounderline abstract_t">Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78:1296.</a></li><li><a class="nounderline abstract_t">Sato T, Nakamura H, Fujieda Y, et al. Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study. Lupus 2019; 28:1577.</a></li><li><a class="nounderline abstract_t">Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med 2019; 171:685.</a></li><li><a class="nounderline abstract_t">Woller SC, Stevens SM, Kaplan D, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 2022; 6:1661.</a></li><li><a class="nounderline abstract_t">Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349:1133.</a></li><li><a class="nounderline abstract_t">Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3:848.</a></li><li><a class="nounderline abstract_t">Scheen M, Adedjouma A, Esteve E, et al. Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. Autoimmun Rev 2022; 21:103072.</a></li><li><a class="nounderline abstract_t">Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459.</a></li><li><a class="nounderline abstract_t">Hussain H, Tarantino MD, Chaturvedi S, et al. Eculizumab for refractory thrombosis in antiphospholipid syndrome. Blood Adv 2022; 6:1271.</a></li><li><a class="nounderline abstract_t">Vaidya S, Sellers R, Kimball P, et al. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation 2000; 69:1348.</a></li><li><a class="nounderline abstract_t">Vaidya S, Gugliuzza K, Daller JA. Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation 2004; 77:1046.</a></li><li><a class="nounderline abstract_t">Vella J. Significance of anticardiolipin antibodies on short- and long-term allograft survival and function following kidney transplantation. Am J Transplant 2004; 4:1731.</a></li><li><a class="nounderline abstract_t">Friedman GS, Meier-Kriesche HU, Kaplan B, et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 2001; 72:1073.</a></li><li><a class="nounderline abstract_t">Canaud G, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371:303.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Weitz JI. The mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014; 371:369.</a></li><li><a class="nounderline abstract_t">Kaplan AA. The use of apheresis in immune renal disorders. Ther Apher Dial 2003; 7:165.</a></li><li><a class="nounderline abstract_t">Sokunbi DO, Miller F, Wadhwa NK, Nord EP. Reversible renal failure in the primary antiphospholipid syndrome--a report of two cases. J Am Soc Nephrol 1993; 4:28.</a></li></ol></div><div id="topicVersionRevision">Topic 3073 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29791828" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Management of the Antiphospholipid Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36849186" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27708976" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23861221" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29904380" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11224691" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antiphospholipid antibody syndrome and renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27555120" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antiphospholipid syndrome and kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29867982" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal Involvement in Antiphospholipid Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442758" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8371224" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Primary antiphospholipid antibody syndrome, renal infarction and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6442640" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Renal vein thrombosis in systemic lupus erythematosus: association with the "lupus anticoagulant".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antiphospholipid syndrome and renal thrombotic microangiopathy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27198137" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal involvement in primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20430943" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2133426" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anti-cardiolipin antibody and renal disease: a report three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073601" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The intrarenal vascular lesions associated with primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10874055" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15211451" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : ARF and cerebral infarcts in a young woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15334471" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15960149" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Kidney disease associated with primary antiphospholipid syndrome: clinical signs and histopathological features in an case experience of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12164854" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : "Black swan in the kidney": renal involvement in the antiphospholipid antibody syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369854" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-1999. A 54-year-old woman with acute renal failure and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12972481" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800790" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ultrasonographic Evaluation of Resistive Index and Renal Artery Stenosis in Patients with Anti-Phospholipid Syndrome: Two Distinct Mechanisms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592608" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12776272" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The expanding spectrum of renal diseases associated with antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2110431" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178788" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A case of lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8101587" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The antiphospholipid syndrome: ten years on.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8025223" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Renal vascular complications of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11752020" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antiphospholipid syndrome nephropathy in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14712424" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17044463" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Significance of antiphospholipid antibodies in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27336701" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antiphospholipid Antibodies in Lupus Nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23320601" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The spectrum of renal thrombotic microangiopathy in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23302713" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31594451" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antiphospholipid antibodies in patients with lupus nephritis: clinical correlations and associations with long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7474666" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645540" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1956552" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8154497" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8311089" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7885428" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The management of thrombosis in the antiphospholipid-antibody syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883539" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346631" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2509856" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The "primary" antiphospholipid syndrome: major clinical and serological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9921802" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15045124" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Acquired hypercoagulable state in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585313" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15476477" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890320" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A review on management of antiphospholipid syndrome in clinical practice</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31092409" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : EULAR recommendations for the management of antiphospholipid syndrome in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31635559" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31610549" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34662890" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679527" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15869575" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35217200" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24400968" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051999" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Eculizumab for refractory thrombosis in antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10798752" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15087770" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15476466" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Significance of anticardiolipin antibodies on short- and long-term allograft survival and function following kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579303" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25054716" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inhibition of the mTORC pathway in the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25054721" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The mTORC pathway in the antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12918939" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The use of apheresis in immune renal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8400066" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Reversible renal failure in the primary antiphospholipid syndrome--a report of two cases.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
